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mAbstract
Background: Neutrophil extracellular traps (NETs) are a central player in the
host response to bacteria: neutrophils release extracellular DNA (nucleosomes)
and neutrophil elastase to entrap and kill bacteria. We studied the role of NETs
in Burkholderia pseudomallei infection (melioidosis), an important cause of
Gram-negative sepsis in Southeast Asia.
Methods: In a prospective observational study, circulating nucleosomes and neutrophil
elastase were assayed in 44 patients with Gram-negative sepsis caused by B. pseudomallei
(melioidosis) and 82 controls. Functional assays included human neutrophil stimulation
and killing assays and a murine model of B. pseudomallei infection in which NET function
was compromised using DNase. Specified pathogen-free 8- to 12-week-old C57BL/6 mice
were sacrificed post-infection to assess bacterial loads, inflammation, and pathology.
Results: Nucleosome and neutrophil elastase levels were markedly elevated in patients
compared to controls. NETs killed B. pseudomallei effectively, and neutrophils stimulated
with B. pseudomallei showed increased elastase and DNA release in a time- and
dose-dependent matter. In mice, NET disruption with intravenous DNase administration
resulted in decreased nucleosome levels. Although DNase treatment of mice resulted in
diminished liver inflammation, no differences were observed in bacterial dissemination
or systemic inflammation.
Conclusion: B. pseudomallei is a potent inducer of NETosis which was reflected by
greatly increased levels of NET-related components in melioidosis patients. Although NETs
exhibited antibacterial activity against B. pseudomallei, NET formation did not protect
against bacterial dissemination and inflammation during B. pseudomallei-induced sepsis.
Keywords: Sepsis; Burkholderia pseudomallei; Melioidosis; Neutrophil extracellular traps
(NETs); Neutrophils; Diabetes; Survival; DNase; Innate immunityBackground
Melioidosis (Gram-negative infection caused by Burkholderia pseudomallei) is a major
cause of severe community-acquired sepsis in Southeast Asia and northern Australia
[1,2]. The clinical manifestations of B. pseudomallei infection range from chronic skin
abscess to acute fulminant sepsis. Despite antibiotic treatment, melioidosis patients with
bacteremia or pneumonia have a mortality rate of approximately 40% [3,1,2]. Melioidosis
is therefore a good clinical model in which to study Gram-negative sepsis [4-6].2014 de Jong et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
ttribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
edium, provided the original work is properly credited.
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bacteria [7,8]. Their arsenal is impressive and ranges from killing and phagocytosis to
the production and release of antimicrobials and immunoregulatory cytokines [9,2].
Neutrophils play a critical role in the host defense against B. pseudomallei. Although
excessive neutrophil recruitment may be detrimental to the host [10], neutrophils are
essential for early bacterial containment. Activated neutrophils are rapidly recruited to
the lungs upon infection, and neutrophil depletion leads to accelerated mortality in
mice [11,12]. Not surprisingly, conditions that predispose individuals to melioidosis, most
notably diabetes mellitus, are associated with impaired neutrophil function [3,13-15].
Neutrophil extracellular traps (NETs; another effector mechanism of neutrophils)
consist of extracellular DNA and histone-based structures decorated by antimicrobials
such as neutrophil elastase and myeloperoxidase. They ensnare bacteria, degrade
virulence factors, and ultimately kill their target [16]. Besides their antimicrobial
function, NETs also induce a strong procoagulant response via extracellular nucleosomes
(extracellular frames consisting of DNA and histones) within the NETs, which stimulates
the proteolytic activity of neutrophil elastase and in turn promotes coagulation [17-20].
Virtually, all microbes that cause sepsis (including B. pseudomallei) have been shown to
induce NET formation in vitro [7,21,16]. In a mouse model of intraperitoneal Escherichia
coli infection, it was recently shown that NETs released into the vasculature were able to
trap bacteria from the bloodstream and prevent bacterial dissemination [22]. Intriguingly,
some bacteria (such as certain strains of Streptococcus pneumoniae and Pseudomonas
aeruginosa) have developed mechanisms to circumvent NET-mediated killing, for
example, via DNase [21,23,8,19]. In theory, overwhelming NETosis or a reduced
clearance capacity of NETs could be detrimental to the host during sepsis and contribute
to ongoing inflammation, organ damage, and/or exhaustion of the immune system
[21]. In the context of sepsis, free circulating DNA is regarded as an endogenous danger
signal or ‘danger-associated molecular pattern’ (DAMP). DAMPs are released during
inflammatory stress and trigger the host immune response [24-26]. The role and
consequences of NET formation during human sepsis, however, remain ill-defined.
In this study, we examined the expression of NET-related markers in patients with
melioidosis. We examined next the functional role of NETs in an in vitro model of
B. pseudomallei infection, then examined the role of NETs in vivo by treating mice
infected with B. pseudomallei with DNase to disrupt the DNA backbone of NETs.Methods
Studies of clinical melioidosis
The clinical study was approved by the Oxford Tropical Research Ethics Committee
(OXTREC 018-07) and the Ethics Committee of Mahidol University (MUTM 2008-
001-01). This co-host has been described previously [27]: 44 patients with culture-proven
melioidosis and sepsis, from whom ethylenediaminetetraacetic acid (EDTA) plasma was
obtained on day of recruitment, 7 days after, and at a follow-up clinic ≥28 days after
discharge. Patients were recruited within 48 h of admission. All patients had culture-
proven melioidosis and had two out of four criteria for systemic inflammatory response
syndrome (SIRS) [28]. Eligible patients had received active antimicrobial chemotherapy
for less than 48 h (ceftazidime, amoxicillin-clavulanate, meropenem, or imipenem).
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ment or a diagnosis of diabetes made prior to admission. Eighty-two healthy subjects
served as controls (52 with diabetes and 30 without; Additional file 1: Table S1).
Peripheral leukocyte gene expression was determined via microarray analysis, as
described previously [29]. RNA was assayed using HumanWG-6 v3.0 Expression
BeadChips (Illumina®, Illumina Inc., San Diego, CA, USA), and data have been deposited
at ArrayExpress, EMBL-EBI (accession-number E-TABM-852-n). We interrogated this
database for proteins co-localizing to NETs [17]. To assess human neutrophil elastase,
complexes together with α1-antitrypsin were assayed in plasma by ELISA, as elastase in
plasma is immediately inactivated by the formation of these covalent complexes and is
hardly detectable in its active form [30,31]. Nucleosome levels were determined in EDTA
plasma by enzyme-linked immunosorbent assay (ELISA) [32,33]. In brief, the capture
antibody was CLB-ANA/60 (which recognizes histone-3). The detector antibody was
biotinylated CLB-ANA/58 (which recognizes an epitope exposed on complexes of
histone-2A, histone-2B, and dsDNA). The reaction was read using poly-HRP and
3,3′,5,5′-tetramethylbenzidine as the chromogenic substrate.Human neutrophil stimulation
B. pseudomallei strain 1026b [34] was cultured overnight and transferred to fresh Luria
broth for 3 h in a 37°C shaker to yield bacteria at mid log-phase. Staphylococcus aureus
strain LAC (USA 300; a known NET inducer [35]) was grown to stationary phase for
20 h in tryptic soy and brain-heart infusion broth at 37°C. Bacteria were centrifuged for
2 min at 300×g and the resulting pellet resuspended in Hanks' balanced salt solution (HBSS)
with Ca2+ and Mg2+ (HBSS+/+; Gibco, Invitrogen, Carlsbad, CA, USA) before use.
Human neutrophils were isolated from peripheral blood of healthy donors using
Polymorphprep™ (Axis-Shield, Oslo, Norway). Following erythrocyte lysis, neutrophils
were washed and resuspended with HBSS without Ca2+ and Mg2+ (HBSS−/−) [7]; ≥99%
of neutrophils were viable as determined by trypan blue exclusion [36]. Human NETs
were induced as described previously [7,17]. In brief, neutrophils were resuspended in
HBSS−/− (final concentration 2 × 105 cells/100 μL) and infected with 100 μL HBSS+/+
containing live B. pseudomallei (final concentration 2 × 105 to 2 × 107 cfu) at 37°C and
5% CO2 to induce NET formation. HBSS+/+ medium alone served as the negative control;
20 nM phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich Corporation, St. Louis, MO,
USA) and S. aureus (2 × 105 cfu) served as positive controls. Supernatant was harvested at
0, 1, and 4 h and passed through a 0.2-μm filter (Millipore, Billerica, MA, USA) to remove
live bacteria prior to storage at −20°C. For DNA quantification, cells were washed once with
medium before adding HBSS−/−, Ca2+ and Mg2+ (5 mM), and 0.1 U/mL DNase (Roche
Diagnostics, Indianapolis, IN, USA) and incubated for a further 2 h at 37°C. Sterile 20 mM
EDTA (Thermo Scientific, Waltham, MA, USA) was added to stop DNase activity. In
control wells, EDTA was added prior to incubation with DNase.
To examine the growth-inhibiting properties of NETs on B. pseudomallei, 3 × 105
human neutrophils per well were resuspended in 50 μL Iscove's modified Dulbecco's
medium (IMDM; Gibco) in a 96-well plate, then stimulated with 100 nM PMA for 5 h
at 37°C (5% CO2) to induce NET formation [7]. Following NET formation, the cells
were preincubated for 30 min at 37°C with 50 U DNase, heat-inactivated DNase (80°C
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5 mM (Molecular Probes, Eugene, OR, USA) and then visualized using a confocal
microscope (Olympus IX81, Olympus Corporation, Tokyo, Japan). The supernatant was
discarded, and approximately 7 × 102 cfu/100 μL IMDM of log-phase B. pseudomallei
were added to the wells and spun down for 5 min at 300×g. After 10 h, bacterial loads
were quantified by culture on horse blood agar.
Free elastase in the supernatant was assayed by ELISA as in the absence of plasma no
complexes are formed with α1-antitrypsin, as described previously [37,30]. Since NET
formation is quantified by the measurement of DNA release after DNase treatment,
and DNA will degrade the epitope of the anti-nucleosome antibody, measurement of
nucleosomes by this ELISA is not suitable [38]. Therefore extracellular DNA was
quantified in the supernatant using a Quant-iT™ Picogreen® dsDNA Assay Kit (Invitrogen)
according to the manufacturer's instructions and was analyzed with a SpectraFluor Plus
absorbance reader (Tecan Group, Männedorf, Switzerland).Mouse experiments
Mouse experiments were approved by the Academic Medical Center Animal Use and Wel-
fare Committee (DIX16AB). Pathogen-free 8- to 12-week-old C57BL/6 mice (Charles River,
Wilmington, MA, USA) were inoculated intranasally with 1,000 (LD100) or 125 (LD50) cfu
B. pseudomallei 1026b in a 50-μL saline solution (eight per group) as described previously
[39,40]. Mice were treated intravenously with 2,000 U DNase I (Roche) in 200 μL PBS at 0,
4, 20, 26, 42, and 50 h post-inoculation to disrupt the NET backbone; control mice received
200 μL PBS intravenously as described [22]. Lung, broncheoalveolar lavage fluid (BALF),
liver, and EDTA blood were collected for bacterial culture and cytokine assays as described
previously [41]. Nucleosomes were assayed in plasma and BALF to quantify NET formation.
Neutrophil counts in BALF were determined by FACS (FACSCalibur; Becton Dickson,
San Jose, CA, USA) using directly labeled antibodies against Gr-1 (Ly-6G; Gr-1 FITC; BD
Pharmingen, BD Biosciences, San Jose, USA). Nucleosome levels were measured by ELISA
[32,33]. Tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-10, and chemokine (C-X-C
motif) ligand 1 (CXCL1 or KC) in lung homogenates were measured by sandwich ELISA
(R&D Systems, Minneapolis, MN, USA) [41]. Plasma cytokine concentrations (TNF-α, IL-6,
interferon (IFN)-γ, IL-10, monocyte chemotactic protein-1 [MCP-1 or CCL2], and IL-12p70)
were measured by cytometric bead array (BD Biosciences). Lactate dehydrogenase (LDH),
aspartate aminotransferase (AST), alanine transaminase (ALT), urea, and creatinine were
measured in plasma with spectrophotometry (Roche Diagnostics). Lung and liver inflam-
mation were scored histologically as described previously [42,41,40]. In brief, lung inflam-
mation and damage of tissue were analyzed with respect to the following parameters:
surface with pneumonia, necrosis and/or formation of abscess, interstitial inflammation,
endothelialitis, bronchitis, edema, thrombus formation, and pleuritis. Liver pathology was
analyzed with respect to the following parameters: area of liver with parenchymal inflam-
mation, necrosis and/or abscess formation, portal inflammation, and thrombus formation.Statistical analysis
Gene expression data were analyzed using R-Bioconductor, as described previously
[29]. We log-transformed neutrophil elastase and nucleosome concentrations to correct
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reported are for the slope of the linear regression model with elastase or DNA as the
dependent variable and time point or stimulus as independent variables. Differences
between murine groups were analyzed by the Mann-Whitney U or unpaired t test where
appropriate. Analyses were done in GraphPad Prism version 6.0 for Mac OS X (GraphPad
Software), and data are expressed as mean and SD unless stated otherwise.Results
Nucleosome and neutrophil elastase levels are markedly elevated in patients with melioidosis
and correlate with disease severity
To establish the presence of NETs during clinical melioidosis, we measured nucleosomes
(complexes of extracellular DNA and histones and a useful measure of cell-free DNA in
plasma) and neutrophil elastase (a measure of neutrophil degranulation) in the plasma of
44 patients with septic melioidosis and 82 healthy controls. Both are key NET-related
markers [17,18,43], and both nucleosome (P < 0.0001) and elastase levels (P < 0.0001) were
abundant in the plasma of patients with melioidosis on day of recruitment compared to
healthy controls (Figure 1A,D).
The mortality rate of 27% (12 of 44) in this cohort enabled us to correlate the presence
of these NET-related markers with disease severity. No differences were seen in the
admission nucleosome and neutrophil elastase levels when comparing survivors and
non-survivors (Figure 1B,E). No differences were seen in concentration levels of both
NET markers in non-survivors on day of enrollment and day 7. All non-survivors
died before the 28 day time point. However, a marked difference in nucleosomeFigure 1 NET-related markers are abundantly present in plasma from patients with melioidosis with
or without diabetes. Increased levels of NET-related markers such as nucleosomes and neutrophil elastase are
measured in plasma of patients on day of initial presentation with sepsis caused by B. pseudomallei (melioidosis)
compared to healthy control subjects. No difference was found between melioidosis patients with or without
diabetes (A, D). No difference was seen between melioidosis survivors versus non-survivors (B, E). Straight lines
represent the mean, and dashed lines mark the lower limit of detection. Nucleosome levels and neutrophil
elastase were measured in all surviving patients on day of enrollment, day 7, and day 28 (follow-up). There is no
difference when looking at the normalization of the NET-related makers over time between melioidosis patients
with or without diabetes (C, F). Mean and SEM are shown. ***P < 0.001 (unpaired t test).
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point, patients that went on to die had significantly higher nucleosome levels (192.3 ±
5) compared to survivors (33.6 ± 4; P = 0.001). Evidence for an association between
nucleosome and neutrophil elastase plasma levels and disease severity was obtained
in patients who survived, a second blood sample was drawn during treatment (at day 7) and
after successful completion of therapy (≥28 days from discharge). In all surviving patients,
plasma nucleosome and elastase concentrations moved toward normal (Figure 1C,F).
Moreover, neutrophil activation (evidenced by elastase-α1-antitrypsin complexes) was
strongly correlated with nucleosome levels at admission (P < 0.001, Figure 2), supporting
the hypothesis that neutrophils are the source of nucleosomes. Of note, gene expression
of proteins known to be associated with NET formation [17] was determined in total per-
ipheral leukocytes derived from patients with culture-confirmed septic melioidosis and
healthy controls. In line with the protein measurements, a marked up-regulation of
genes encoding the central NET-associated proteins nucleosome histone-2B and
histone-4 was found (Additional file 2: Table S2).
No influence of diabetes on the release of the NET-related markers
Since diabetes is the main risk factor for melioidosis and diabetes is known to negatively
influence neutrophil function [3,15,14], we next sought to determine whether the pres-
ence of diabetes influenced the release of NET-related markers in our cohort of patients
of whom 72% were diabetic. We found no difference in the release of the NET-related
markers in melioidosis when comparing patients with or without diabetes on day of re-
cruitment. In addition, NET-related markers were not different in healthy controls with
or without diabetes (Figure 1A,D).
Elastase and extracellular DNA are released by neutrophils in a dose- and time-dependent
fashion upon stimulation with B. pseudomallei
To examine whether neutrophils were the common source of NET-related marker release
in patients with melioidosis, we isolated human neutrophils from healthy individuals and
stimulated them with various known NET inducers as well as B. pseudomallei upon whichFigure 2 Neutrophil elastase and nucleosome release are highly correlated in patients with melioidosis.
Linear regression of neutrophil elastase versus nucleosomes. Correlation coefficient reported is for Pearson's r.
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Consistent with the patient data, elastase levels increased following stimulation with
B. pseudomallei, and this occurred in a dose-dependent (P < 0.001, Figure 3A) and time-
dependent manner (P = 0.005, Figure 3C). Extracellular DNA release also increased in a
time- and dose-dependent manner following B. pseudomallei infection: extracellular DNA
concentrations increased as the multiplicity of infection (MOI) increased (P < 0.001,
Figure 3C) and over time (P < 0.001, Figure 3D). Of note, B. pseudomallei-infected
cells released similar amounts of elastase and DNA as S. aureus (Additional file 3:
Figure S1), itself a potent NET inducer [44]. Elastase levels and DNA release were
also strongly correlated, reflecting the clinical data (Figure 3E).NETs exhibit antibacterial activity against B. pseudomallei
We next sought to examine whether activated NETs were able to kill B. pseudomallei.
We pre-stimulated human neutrophils with PMA for 5 h to induce NET formation
[7,17], then preincubated the cells with PBS or DNase prior to infection with B.
pseudomallei. Extracellular degradation of DNA by DNase treatment was confirmed
by confocal microscopy (Figure 4A,B). Disrupting the backbone of the NETs with
active DNase impaired the killing of B. pseudomallei by NETs from human neutrophils
(Figure 4C). Taken together, these data confirm the involvement of NETs in the killing of
B. pseudomallei by neutrophils.Figure 3 NET-related markers are released by neutrophils in a dose- and time-dependent fashion.
The kinetics of B. pseudomallei-induced NET formation at various multiplicities of infections (MOI; 10°, 101,
102) and time points (0, 1, and 4 h) were assessed by quantifying elastase (A, C) and extracellular DNA
using a Picogreen dsDNA kit (B, D), in the supernatant of stimulated isolated human neutrophils. The
negative control (−) was medium (HBSS−/−), and the positive control (+) was PMA, a known inducer of
NETs. Both elastase and DNA increase in a time- and dose-dependent manner following B. pseudomallei
(Bps) stimulation. The mean and SD are expressed. (E) The two NET markers, elastase and DNA, were highly
correlated, suggesting that neutrophils are the source of this extracellular DNA. All experiments used whole
blood from three to six different healthy human volunteers. Elastase results were log-transformed to correct
for heteroscedasticity. P values reported are for the slope of linear regression models with elastase or DNA
as the dependent variables and time point or MOI as independent variables. **P < 0.01; ***P < 0.001.
Figure 4 NETs exhibit antibacterial activity against B. pseudomallei. Representative confocal micrographs
of human neutrophils stimulated with PMA (A) to produce NETs and post-stimulation treated with PBS,
heat-inactivated (HI) DNase, or active DNase (B), before infection with 7 × 102 cfu B. pseudomallei (C). Data are
expressed as mean and SD. P value was determined via one-way ANOVA. Blood from three different healthy
human volunteers was used.
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Having confirmed that NETs are capable of killing of B. pseudomallei in vitro, we
sought to replicate this finding in a murine model of melioidosis. We infected mice
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venous DNase twice daily in order to disrupt NET formation, as described previously
[22]. Animals were sacrificed after 24 or 72 h to determine bacterial loads in BALF and
lung (primary sites of the infection), and the liver and blood (to evaluate the extent of
bacterial dissemination). In this murine model of Gram-negative sepsis, untreated mice
showed an increase of nucleosome levels in plasma (17.6 ± 15) and BALF (202.7 ± 110)
24 h post-infection (Figure 5A,D). In comparison, uninfected untreated mice (t = 0)
had low to undetected plasma and BALF nucleosome levels (5.6 ± 3 and 12.9 ± 5,
respectively). DNase treatment resulted in successful disruption of intravascular NET
formation, as illustrated by significantly decreased nucleosome levels in both plasma
(5.3 ± 3, P = 0.03) and BALF (93.9 ± 29, P = 0.02) compared to untreated mice 24 h
post-infection (Figure 5A,D). Disruption of intravascular NETs did not, however,
result in changes in bacterial loads in BALF, lung, blood, or liver (Figure 5). In line
with the bacterial loads, no differences were seen in total cell count or neutrophil
influx in BALF between DNase-treated and untreated mice after infection (data not
shown). Because cytokines are important regulators of the inflammatory response to
bacterial pneumonia [45], we measured pulmonary (TNF-α, IL-6, IL-10, CXCL1)
and systemic (TNF-α, MCP-1, IL-6, IFN-γ, IL-10, IL12p70) cytokine and chemokine
levels (Table 1). Levels of all cytokines were elevated in both pulmonary and systemic
compartments (with the exception of IL-10) upon B. pseudomallei infection. However, in
complete correspondence with bacterial loads and cellular influx, no differences were seen
between the DNase-treated animals and controls.
We speculated that the infectious challenge might have been too high to reveal an
effect of NET blockade in our model and therefore repeated the experiments with a
lower inoculum (1.25 × 102 cfu which is the LD50). Again, although significant reductionsFigure 5 Disruption of NETs does not influence bacterial dissemination during experimental melioidosis.
C57/Bl6 wild-type (WT) mice were intranasal infected with B. pseudomallei (103 cfu) and either treated with
intravenous PBS (control group) or 2,000 U DNase I recombinant (DNase-treated group) at various time
points [22]. Compared to control mice, DNase-treated mice show reduced nucleosome levels in plasma (A) and
bronchoalveolar lavage fluid (BALF) (D) after 24 h of infection. Data are expressed as box-and-whisker diagrams
depicting the smallest observation, lower quartile, median, upper quartile, and largest observation. Equal bacterial
titers were seen in BALF (B), lung homogenates (C), blood (E), and liver homogenates (F) during all time points
after infection in the DNase I-treated mice compared to control mice. Median values (straight lines) and the lower
limit of detection (dashed lines) are shown. Graphs depict eight mice per group and time point. Statistical
significance was determined using the unpaired Mann-Whitney U test. *P < 0.05.
Table 1 Cytokines and markers for systemic organ injury do not differ between mice
treated with intravenous DNase or PBS post-infection with B. pseudomallei
24 h 72 h
Control DNase P value Control DNase P value
Plasma
TNF-α (pg/mL) 3.3 ± 2 4.1 ± 2 0.41 407 ± 319 328.3 ± 300 0.62
MCP-1 (pg/mL) 11.7 ± 13 21.5 ± 8 0.09 3,976 ± 2,183 2,879 ± 1,937 0.31
IL-12p70 (pg/mL) ND ND 8.6 ± 10 21.6 ± 20 0.13
IL-6 (pg/mL) 115.3 ± 73 104 ± 62 0.74 8,022 ± 3,814 6,990 ± 4,252 0.62
IFN-γ (pg/mL) 4.0 ± 6 4.8 ± 4 0.76 1,914 ± 1,152 1,791 ± 1,490 0.86
IL-10 (pg/mL) ND ND ND ND
AST (U/L) 63.6 ± 6 74.4 ± 37 0.83 356.6 ± 191 247 ± 143 0.50
ALT (U/L) 21.7 ± 9 27 ± 24 0.92 155.4 ± 59 138 ± 98 0.60
LDH (U/L) 210 ± 74 312.9 ± 157 0.21 1,115 ± 758 873.2 ± 375 0.71
Urea (mmol/L) 9.8 ± 2 7.7 ± 2 0.04 15.9 ± 10 14.4 ± 5 0.91
Creatinine (μmol/L) 11.3 ± 2 9.6 ± 4 0.43 15.7 ± 17 8.4 ± 7 0.53
Lung
TNF-α (pg/mL) 239.1 ± 110 427.8 ± 100 0.003 3,182 ± 1,440 3,261 ± 1,382 0.91
IL-6 (pg/mL) 945.9 ± 348 1,103 ± 201 0.29 8,601 ± 3,329 7,521 ± 3,482 0.54
IL-10 (pg/mL) 205.8 ± 147 266.4 ± 57 0.29 559.4 ± 219 498.3 ± 107 0.49
CXCL1 (pg/mL) 6,771 ± 4,247 6,147 ± 2,284 0.72 26,421 ± 10,123 26,305 ± 10,450 >0.99
Cytokines and markers for systemic organ injury were measured in plasma and/or lung homogenates 24 and 72 h
post-infection. Data are means ± SD (cytokines) or median (range) of five to eight mice per group. Actual P values are shown,
determined via t test or Mann-Whitney U where appropriate; ND, not detectable or below detection limit; TNF-α, tumor
necrosis factor-alpha; MCP-1, monocyte chemo-attractive protein-1; IL, interleukin; IFN-γ, interferon-gamma; AST, aspartate
transaminase; ALT, alanine transaminase; LDH, lactate dehydrogenase; CXCL1, chemokine (C-X-C motif) ligand 1.
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untreated mice, no differences were seen in bacterial burdens in BALF, lung, blood, or
liver nor local or systemic inflammatory cytokine levels 72 h post-infection (data not
shown). These results indicate that disrupting NET release by degradation of the
DNA backbone does not impair the host defense against B. pseudomallei infection.
Intravascular NETs cause collateral liver damage during experimental melioidosis
It has been reported previously that NETs are implicated in tissue damage during E. coli
sepsis [22]. We therefore examined lung and liver tissue histologically for inflammation.
No differences in lung pathology scores were observed between groups (Figure 6A,B,C).
In accordance with a previous report, however, we found that significantly less liver
inflammation was seen in the DNase-treated group when compared to controls at 72 h
post-infection (P = 0.04, Figure 6D,E,F). It should be noted, however, that serum levels of
AST and ALT, both markers of hepatocellular injury, as well as urea, creatinine, and LDH,
markers of kidney and systemic organ injury, showed a trend toward lower values in the
DNase-treated mice, although this did not reach statistical significance (Table 1). We con-
clude that there is only a limited role for NETs during B. pseudomallei infection in vivo.
Discussion
NETs have emerged as key players in the innate host response to many bacteria.
Neutrophils release extracellular DNA (including nucleosomes) and neutrophil elastase to
Figure 6 Effect of DNase treatment on pulmonary and hepatic inflammation after infection with B.
pseudomallei. Representative hematoxylin and eosin stained slides of lung (A, B) and liver (D, E) of control
and DNase-treated mice 72 h post-infection with B. pseudomallei (103 cfu). Marked inflammation was seen
post-infection, and areas of necrosis (marked with a number sign) and thrombosis formation (marked with
an asterisk) were seen in both groups. Significantly less liver inflammation was observed in the DNase-treated
group when compared to controls 72 h after infection. Total organ pathology score (lung and liver (C, F)) was
determined 24 and 72 h post-infection according to the scoring system as described [41,39,40]. Graphs depict
eight mice per group and time point. Median values are shown, and statistical significance was determined
using the unpaired Mann-Whitney U test. *P < 0.05.
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susceptible to B. pseudomallei infection [12]. Our study extends the description of the role
of NETs in the host response to Gram-negative sepsis caused by B. pseudomallei in
both clinical melioidosis and a murine model of melioidosis. We found that the key
NET components, nucleosomes and neutrophil elastase, were both elevated in clinical
melioidosis. In vitro observations supported the notion that neutrophils are the source
of these proteins and isolated human neutrophils infected with B. pseudomallei released
NET-related markers in a time- and dose-dependent manner. We further showed that
NETs killed B. pseudomallei in an in vitro human neutrophil infection model, although in
a murine model of experimental melioidosis, in which DNase was used to disrupt
NET formation, no protective role for NETs in the host defense against B. pseudomallei
infection could be demonstrated.
Our data corroborate a previous report in which it was shown that bactericidal NETs
were released from human neutrophils in response to B. pseudomallei in an in vitro
model [46]. In addition, we recently showed that inhibition of endogenous activated
protein C, which exerts cytoprotective effects on the endothelium by cleavage of histones
[47], leads to excessive nucleosome release in BALF during murine experimental melioid-
osis [48]. We now demonstrate that there is an abundant release of NET-related markers
in plasma from melioidosis patients. In vitro experiments demonstrated that NET-related
markers are released by neutrophils and exhibit NET-dependent antibacterial activity
upon infection with B. pseudomallei.
Surprisingly, we found that NETs played no role in bacterial clearance in our experimental
mouse model of sepsis. In DNase-treated mice, circulating nucleosomes were decreased but
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argues against a role for nucleosomes (which can become harmful to the host when released
in excessive amounts [25,26]) as significant endogenous danger signals in melioidosis. This
correlates with our clinical finding that the concentration of circulating NET markers in
melioidosis patients was not different between survivors and non-survivors on day of
admission. We did however find a difference between survivors and non-survivors on day
7, which is in line with our previous finding that circulating nucleosomes correlated with
severity of the inflammatory response and outcome in a cohort of children suffering from
meningococcal sepsis [49].
ELISAs detecting nucleosomes have proven to be a good indicator of NET release in
patients [43] but are not specific for nucleosomes released by neutrophils. We therefore
cannot exclude that nucleosomes released into the circulation by other cell types, such as
endothelial and parenchymal cells, are detected as well. However, the positive correlation
with neutrophil elastase together with the marked up-regulation of genes encoding
the central NET-associated proteins does suggest that neutrophils are the main source
of the detected nucleosomes. Although B. pseudomallei can induce NET release,
NETs are predominantly a mechanism for clearing extracellular pathogens, and B.
pseudomallei may escape NETosis by hiding intracellularly [50,21,51]. Indeed, it was
found that both the type 3 secretion system (an important virulence factor of B.
pseudomallei) and the bacterial capsule may play a role in evading NETs [46].
Furthermore, one could hypothesize that like S. aureus [52], B. pseudomallei is able
to cause leukocyte toxicity by converting NETs into a bioproduct thereby inducing
macrophage apoptosis. However, this mechanism would be unfavorable for B. pseu-
domallei as it is already known that macrophage destruction is one of the host
immune defense strategies to restrict intracellular growth of B. pseudomallei [2]. Another
possibility could be that plasma from patients with severe sepsis induces platelet-
neutrophil interactions in a TLR4-dependent fashion leading to the production of NETs
[53,22], whereas TLR4 does not seem to play an important role in the clearance of
B. pseudomallei [2,41].
At least a third of all patients with melioidosis have diabetes mellitus as a predisposing
factor [3,1,2]. An explanation for this increased susceptibility was sought in the function
of neutrophils from diabetic patients, which displayed impaired phagocytosis of B.
pseudomallei, reduced migration, and the inability to produce an oxidative burst to
kill intracellular bacteria [54]. Furthermore, it was shown that isolated neutrophils from
patients with diabetes mellitus released less extracellular DNA upon in vitro stimulation
with B. pseudomallei, which was associated with a reduced bacterial killing capacity when
compared to neutrophils derived from healthy controls [46]. However, in our study, we
did not observe a difference in the release of NET-related markers between diabetic and
non-diabetic melioidosis patients. The combination of clinical data and data from our
murine model argues against an important role for the NETs in melioidosis. Our data also
suggest that impaired NET release does not provide an explanation for the increased
susceptibility to B. pseudomallei infection in patients with diabetes.
NET formation may also injure the host [21]: our finding that DNase-treated mice
have diminished hepatocellular injury after infection is consistent with previous reports
in which mice deficient in NET components have decreased hepatocellular inflamma-
tion compared to controls in an E. coli-induced sepsis model [55,22].
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We have shown that B. pseudomallei is a potent inducer of NETosis, as reflected by
increased concentrations of NET-related components in patients with melioidosis.
Although NETs exhibit antibacterial activity against B. pseudomallei in vitro, NET
formation does not protect against bacterial dissemination and inflammation in a
murine model of B. pseudomallei infection. This correlates with our clinical finding
that levels of NET components do not correlate with mortality.
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Extracellular DNA was measured using a Picogreen dsDNA kit. Mean and SDs are shown. P value comparing Bps,
SA, and PMA to medium control was determined via unpaired t test after log transformation of the data. Blood
from three to six different healthy human volunteers were used. P values *< 0.05, **< 0.01, ***< 0.001 are shown.
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